Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Date:6/30/2008

-- Peregrine's Second Phase II Bavituximab Cancer Trial Is Evaluating the Anti-Tumor Activity of Bavituximab in Combination with Carboplatin and

Paclitaxel --

TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that patient screening and dosing has begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC). The primary objective of the study is to assess the overall response rate to the combination of bavituximab with a standard regimen of carboplatin and paclitaxel in NSCLC patients. The multi-center clinical trial is being conducted in India.

"The initiation of patient enrollment and dosing in our trial of bavituximab in combination with chemotherapy in lung cancer patients marks an important milestone in our Phase II bavituximab clinical program," said Steven W. King, president and CEO of Peregrine. "We are eager to test the combination of bavituximab with carboplatin and paclitaxel in these patients, since 50% of advanced cancer patients treated with this combination in our Phase Ib trial achieved an objective tumor response. We look forward to learning more about bavituximab's potential in NSCLC, an important new indication that is a leading cause of cancer deaths for both men and women."

In the trial's two-stage design, up to 21 patients with NSCLC will be enrolled initially. The study will then be expanded up to a total of 49 patients if promising results are observed in the initial cohort. Secondary objectives of the study include time to tumor progression, duration of response, overall patient survival and
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
2. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
5. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
6. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
7. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
8. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... OXIS International, Inc. (OTC Bulletin Board: OXIS ... named former Wal-Mart executive Ken Eaton to its Board ... including three independent Directors. "I am very ... the OXIS International Board of Directors," said Anthony J. ...
... June 27, 2011 Pacira Pharmaceuticals, Inc ., ... company, today announced that it has been included in ... its comprehensive set of U.S. and global equity indexes ... 3000 Index measures the performance of the 3,000 largest ...
Cached Medicine Technology:OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 2OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
(Date:7/25/2014)... According to the Liver Cirrhosis ... Vkool.com, this is a comprehensive guide that provides ... safe remedies for liver cirrhosis . This ...     Chapter 1: Liver Cirrhosis Bible & ... About Liver Basics ,     Chapter 3: Getting ...
(Date:7/24/2014)... (PRWEB) July 25, 2014 Journal ... be affected by the width of the alveolar ridge—an ... the implant. A variety of methods exist, each with ... augmentation techniques. The ridge-split graft is highlighted as a ... Journal of Oral Implantology offers a comparison of ...
(Date:7/24/2014)... PROVIDENCE, R.I. [Brown University] The U.S. Preventive ... lung screening for people at high risk for ... that many patients will have positive results on ... on further testing. Many policymakers have expressed concern ... to become needlessly upset. A new study of ...
(Date:7/24/2014)... Voted one of the most reliable online ... focuses on providing its new and old customers with ... company has announced its new collection of high end ... created according to the latest fashion trends. Additionally, they ... off. , As a matter of fact, high end ...
(Date:7/24/2014)... 24, 2014 Four Seasons Resort ... of its $3 million renovation of the famed Maile ... three-bedroom suites, just in time to welcome summer guests ... design direction from the internationally-acclaimed BraytonHughes Design Studios, San ... the property and the largest in Hawaii—received a complete ...
Breaking Medicine News(10 mins):Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5
... ... the United States will be working in the fields. Although the United States was one ... continues to allow children to work long hours in hazardous jobs. , ... Washington, D.C.(Vocus) June 11, 2010 -- Today on ...
... ... distribution operations for the company’s new product line, the CR Series Load & Go™ ... ... of a new manufacturing facility in Miramar, Florida. The new facility will support ...
... ... Advanced Imaging Consultants have finalized their partnership, that will make UltraLinq,s exam reporting ... and operations solution for mobile and outreach imaging businesses. , ... New York, NY (PRWEB) ...
... blood supply, but urge more research , SATURDAY, June 12 (HealthDay ... panel of experts on Friday voted to uphold a decades-old ban ... the controversial issue. , The current policy -- put into effect ... prevents any man who since 1977 has had sex with another ...
... will be ineffective , SATURDAY, June 12 (HealthDay ... to treatment for hepatitis C infection has been identified ... 1,362 hepatitis C patients and pinpointed the variant in ... occurs in a gene called IL28B, which encodes for ...
... Leading Gulf Coast medical centers, universities and public health ... a consortium to improve community disaster readiness and recovery ... environmental health. The consortium, known as SECURE ... funded through a two-year, $4 million grant from the ...
Cached Medicine News:Health News:AFOP's Children in the Fields Campaign Raises Awareness of Child Labor in the U.S. 2Health News:AFOP's Children in the Fields Campaign Raises Awareness of Child Labor in the U.S. 3Health News:UltraLinq Healthcare Solutions and Advanced Imaging Consultants Partner to Provide an Anytime, Anywhere Image Management Solution to the Mobile Market 2Health News:UltraLinq Healthcare Solutions and Advanced Imaging Consultants Partner to Provide an Anytime, Anywhere Image Management Solution to the Mobile Market 3Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 2Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 3Health News:Research alliance aims to help vulnerable communities cope with disaster 2Health News:Research alliance aims to help vulnerable communities cope with disaster 3Health News:Research alliance aims to help vulnerable communities cope with disaster 4
... is the premium CPAP device in ResMeds new ... line of flow generators are the smallest on ... to include an option of fully integrated heated ... for simplicity and convenience. Premium S8 models also ...
... freedom and flexibility with the integrated ... battery pack, the system will be ... Also includes an integrated heated humidifier. ... water for one nights use, and ...
... is the smallest and lightest continuous positive ... It is designed to help active sleep ... with therapy. The GoodKnight 420S model records ... data. It also detects persistent residual apnea, ...
The clarity and performance of glass with shatterproof safety of plastic....
Medicine Products: